Prelude Capital Management, LLC Infla Rx N.V. Transaction History

Prelude Capital Management, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$1.47 - $2.03 $285,863 - $394,763	194,465 New	194,465 $299,000
Q3 2023 Nov 14, 2023	BUY	$2.66 - $4.33 $26,469 - $43,087	9,951 Added 22.0%	55,192 $164,000
Q2 2023 Aug 14, 2023	BUY	$2.05 - $6.1 $92,744 - $275,970	45,241 New	45,241 $201,000
Q2 2019 Aug 14, 2019	SELL	$3.06 - $51.61 $385 - $6,502	-126 Closed	0 $0
Q1 2019 May 15, 2019	SELL	$31.16 - $48.62 $467 - $729	-15 Reduced 10.64%	126 $5,000
Q4 2018 Feb 14, 2019	BUY	$23.33 - $36.37 $3,289 - $5,128	141 New	141 $5,000
Q3 2018 Nov 14, 2018	SELL	$29.34 - $35.0 $2,992 - $3,570	-102 Closed	0 $0
Q2 2018 Aug 14, 2018	SELL	$27.33 - $41.46 $1,448 - $2,197	-53 Reduced 34.19%	102 $3,000
Q1 2018 May 15, 2018	BUY	$20.21 - $32.0 $3,132 - $4,960	155 New	155 $4,000

13.2M

5.2K

Ticker IFRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,203,800
Market Cap $61M
Description
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a nov...

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Prelude Capital Management, LLC with notifications on news.